Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Lubomira Iz&aacute;kov&aacute;1, Ivan Andre1, Angelos Halaris21Psychiatric Clinic, Faculty of Medicine Comenius University and Faculty Hospital, Bratislava, Slovakia; 2Department of Psychiatry and Behavioral Neurosciences, Loyola University Medical Center, Maywood, IL, USAAbstract: S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lubomira Iz&aacute;kov&aacute;, Ivan Andre, Angelos Halaris
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/24f36bf865284c8d933ad64e57b318a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24f36bf865284c8d933ad64e57b318a1
record_format	dspace
spelling	oai:doaj.org-article:24f36bf865284c8d933ad64e57b318a12021-12-02T02:09:58ZCombination therapy or monotherapy for the depressed type of schizoaffective disorder1176-63281178-2021https://doaj.org/article/24f36bf865284c8d933ad64e57b318a12009-02-01T00:00:00Zhttp://www.dovepress.com/combination-therapy-or-monotherapy-for-the-depressed-type-of-schizoaff-a2856https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Lubomira Iz&aacute;kov&aacute;1, Ivan Andre1, Angelos Halaris21Psychiatric Clinic, Faculty of Medicine Comenius University and Faculty Hospital, Bratislava, Slovakia; 2Department of Psychiatry and Behavioral Neurosciences, Loyola University Medical Center, Maywood, IL, USAAbstract: Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the efficacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75&ndash;3.29 mg/day, haloperidol: 5.35&ndash;4.15 mg/day, sertraline: 65.39&ndash;133.82 mg/day. Efficacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically significant greater improvement than haloperidol-sertraline patients on efficacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich&rsquo;s Quality of Life Scale). Risperidone has higher antipsychotic efficacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant efficacy.Keywords: schizoaffective disorder, depressed type, risperidone, haloperidol, sertraline Lubomira Iz&aacute;kov&aacute;Ivan AndreAngelos HalarisDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 91-101 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Lubomira Iz&aacute;kov&aacute; Ivan Andre Angelos Halaris Combination therapy or monotherapy for the depressed type of schizoaffective disorder
description	Lubomira Iz&aacute;kov&aacute;1, Ivan Andre1, Angelos Halaris21Psychiatric Clinic, Faculty of Medicine Comenius University and Faculty Hospital, Bratislava, Slovakia; 2Department of Psychiatry and Behavioral Neurosciences, Loyola University Medical Center, Maywood, IL, USAAbstract: Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the efficacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75&ndash;3.29 mg/day, haloperidol: 5.35&ndash;4.15 mg/day, sertraline: 65.39&ndash;133.82 mg/day. Efficacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically significant greater improvement than haloperidol-sertraline patients on efficacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich&rsquo;s Quality of Life Scale). Risperidone has higher antipsychotic efficacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant efficacy.Keywords: schizoaffective disorder, depressed type, risperidone, haloperidol, sertraline
format	article
author	Lubomira Iz&aacute;kov&aacute; Ivan Andre Angelos Halaris
author_facet	Lubomira Iz&aacute;kov&aacute; Ivan Andre Angelos Halaris
author_sort	Lubomira Iz&aacute;kov&aacute;
title	Combination therapy or monotherapy for the depressed type of schizoaffective disorder
title_short	Combination therapy or monotherapy for the depressed type of schizoaffective disorder
title_full	Combination therapy or monotherapy for the depressed type of schizoaffective disorder
title_fullStr	Combination therapy or monotherapy for the depressed type of schizoaffective disorder
title_full_unstemmed	Combination therapy or monotherapy for the depressed type of schizoaffective disorder
title_sort	combination therapy or monotherapy for the depressed type of schizoaffective disorder
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/24f36bf865284c8d933ad64e57b318a1
work_keys_str_mv	AT lubomiraizampaacutekovampaacute combinationtherapyormonotherapyforthedepressedtypeofschizoaffectivedisorder AT ivanandre combinationtherapyormonotherapyforthedepressedtypeofschizoaffectivedisorder AT angeloshalaris combinationtherapyormonotherapyforthedepressedtypeofschizoaffectivedisorder
_version_	1718402637767901184

Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Ejemplares similares